- Discussion on critical points for a tailored therapy to cure hepatitis C virus infection
-
Marascio N, Quirino A, Barreca GS, Galati L, Costa C, Pisani V, Mazzitelli M, Matera G, Liberto MC, Focà A, Torti C
- KMID: 2447247
- Clin Mol Hepatol.
- 2019 Mar;25(1):30-36.
- doi: 10.3350/cmh.2018.0061
Hepatitis C virus (HCV) infects around 71 million people worldwide and in 2018 it is still a major health problem. Since 2011, anti-HCV therapy with availability of direct-acting antiviral drugs... -
- CITED
-
- Close
- SHARE
-
- Close
- Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals
-
Strazzulla A, Coppolino , Barreca GS, Gentile I, Rivoli L, Postorino , Mazzitelli M, Greco G, Costa C, Pisani V, Marascio N, Simeoni M, Focà A, Fuiano G, Foti D, Gulletta E, Torti C
- KMID: 2417062
- Clin Mol Hepatol.
- 2018 Jun;24(2):151-162.
- doi: 10.3350/cmh.2017.0059
BACKGROUND/AIMS: Correct renal function evaluation is based on estimated glomerular filtration rates (eGFR) and complementary renal damage biomarkers, such as neutrophil gelatinase associated lipocalin (NGAL). The aim of this study... -
- CITED
-
- Close
- SHARE
-
- Close
